

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Diane Clayton and Rebecca Rutter

**Application No.** 10/561,713

**Filed:** December 21, 2005

**Confirmation No.** 1023

**For:** INFLAMMATORY DISEASE TREATMENT

**Examiner:** not yet assigned

**Art Unit:** 1623

**Attorney Reference No.** 5585-72843-01

**FILED VIA EFS ON  
FEBRUARY 22, 2010**

SUBMITTED VIA ELECTRONIC FILING SYSTEM  
UNITED STATES PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language and/or non-English-language documents. The relevance of the non-English language documents can be ascertained by the English-language abstract attached to each document. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement (IDS) before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. § 1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Sheree Lynn Rybak/  
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

cc: Docketing